Literature DB >> 23190624

Polypharmacy with antidepressants in children and adolescents.

Covadonga M Díaz-Caneja1, Ana Espliego1, Mara Parellada1, Celso Arango1, Carmen Moreno1.   

Abstract

The aim of this study was to review current epidemiological data on the use of antidepressants in co-prescription with other psychotropic drugs in children and adolescents, as well as available efficacy and safety information. A Medline search from inception until February 2012 was performed to identify epidemiological and clinical studies, reviews and reports containing potentially relevant information on polypharmacy with antidepressants in young people. There has been an increase in polypharmacy in children and adolescents involving antidepressants in recent years. Antidepressants have become one of the drug classes most frequently prescribed in combination and are commonly co-prescribed with stimulants and antipsychotics. Most information regarding efficacy and safety of polypharmacy patterns was provided by case series and open-label studies. Efficacy studies gave some support for the use of a combination of antidepressants and antipsychotics in the management of refractory obsessive-compulsive disorder and some residual symptoms in major depressive disorder. Even less empirical support was found for a combination of stimulants and antidepressants in co-morbid attention deficit hyperactivity disorder and mood or anxiety disorders. Adverse events were similar to those found with individual medication groups, with severe adverse events mostly reported by individual case reports. The use of polypharmacy with antidepressants has become a regular practice in clinical settings. Although there is still little efficacy and safety information, preliminary evidence points to the potential clinical usefulness of some polypharmacy patterns. Further research on patients with co-morbidities or more severe conditions is needed, in order to improve knowledge of this issue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190624     DOI: 10.1017/S1461145712001265

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  7 in total

1.  Treating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications.

Authors:  Greta A Bushnell; Scott N Compton; Stacie B Dusetzina; Bradley N Gaynes; M Alan Brookhart; John T Walkup; Moira A Rynn; Til Stürmer
Journal:  J Clin Psychiatry       Date:  2018 Jan/Feb       Impact factor: 4.384

2.  Use of SSRIs among Danish children: a nationwide study.

Authors:  Anton Pottegård; Helga Zoëga; Jesper Hallas; Per Damkier
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-02-04       Impact factor: 4.785

3.  Polypharmacy among children and adolescents with psychiatric disorders in a mental referral hospital in Botswana.

Authors:  Anthony A Olashore; Ambrose Rukewe
Journal:  BMC Psychiatry       Date:  2017-05-10       Impact factor: 3.630

4.  Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders.

Authors:  Hilario Blasco-Fontecilla
Journal:  J Neural Transm (Vienna)       Date:  2018-04-06       Impact factor: 3.575

5.  Prescribing patterns of polypharmacy in Korean pediatric patients.

Authors:  Soo-Min Jeon; Susan Park; Sandy Jeong Rhie; Jin-Won Kwon
Journal:  PLoS One       Date:  2019-10-01       Impact factor: 3.240

6.  A whole of population retrospective observational study on the rates of polypharmacy in New Zealand 2014 to 2018 Polypharmacy in New Zealand: What is the current status?

Authors:  James Nind; Alesha Smith; Manjula Devananda; Benoit Auvray
Journal:  Health Sci Rep       Date:  2021-03-10

7.  Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice.

Authors:  Karin M Egberts; Manfred Gerlach; Christoph U Correll; Paul L Plener; Uwe Malzahn; Peter Heuschmann; Stefan Unterecker; Maike Scherf-Clavel; Hans Rock; Gisela Antony; Wolfgang Briegel; Christian Fleischhaker; Alexander Häge; Tobias Hellenschmidt; Harmut Imgart; Michael Kaess; Andreas Karwautz; Michael Kölch; Karl Reitzle; Tobias Renner; Su-Yin Reuter-Dang; Christian Rexroth; Gerd Schulte-Körne; Frank M Theisen; Susanne Walitza; Christoph Wewetzer; Stefanie Fekete; Regina Taurines; Marcel Romanos
Journal:  Pharmacopsychiatry       Date:  2022-02-07       Impact factor: 2.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.